Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma - Concepedia

Concepedia

Publication | Open Access

Preliminary Efficacy of the Anti-Insulin–Like Growth Factor Type 1 Receptor Antibody Figitumumab in Patients With Refractory Ewing Sarcoma

DOI Full Paper Access

209

Citations

17

References

2011

Year

Heribert Juergens, Najat C. Daw, Birgit Geoerger, Stefano Ferrari, Milena Villarroel, Isabelle Aerts, Jeremy Whelan, Uta Dirksen, Mary L. Hixon, Donghua Yin,

Journal of Clinical Oncology

Abstract

Figitumumab had modest activity as single agent in advanced ES. A strong association between pretreatment serum IGF-1 and survival benefit was identified.

References

	Year	Citations

Page 1